HCFA Cost Considerations In Proposed Drug Coverage Criteria To Be Revised
The Health Care Financing Administration plans to eliminate or significantly scale back the role of cost in its proposed criteria for making Medicare drug coverage decisions, the agency indicated after receiving comments on its May 16 notice of intent to publish a proposed rule.
You may also be interested in...
The Health Care Financing Administration would consider cost in deciding whether Medicare should cover a medical technology that employs the same "clinical modality" as an alternative treatment used for the same indication and already covered by Medicare.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials